Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: An international Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

 


An international Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)


Trial Focus

Kidney Cancer

Objective

         This is a clinical trial of autologous dendritic dell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma.

IRB Protocol #

13-1546

Trial Status

OPEN

Principle Investigator

ELAINE LAM

Sponsor

Argos Therapeutics

Contact

MARY ANDUHA at (720)848-0659 or MARY.ANDUHA@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. Your involvement in the pre-screening tumor collection part of this study ends after a part of your kidney tumor is removed. If it is determined that you have a type of advanced kidney cancer called clear cell renal cancer, the study doctor will discuss the duration of the treatment part of this study and all details of the treatment part of the study with you. // Eligibility criteria include but are not limited to 18 years or older with advanced renal cell carcinoma.Eligibility criteria include but are not limited to 18 years or older with advanced renal cell carcinoma.